-
ASPE share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of ASPE shares has increased $0.68 since the market last closed. This is a 5.78% rise.
-
Closed at $12.44.
The stock has since risen $0.25 in after-hours trading.
Key terms
About ASPE
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
-
Market cap: $361.74M
A market capitalization between $300 million and $2 billion places ASPE in the small capitalization category.
Key terms
ASPE Financials
-
ASPE total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
ASPE net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
ASPE earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
ASPE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ASPE Competitors
-
How competitors are chosen
ASPE's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $361.74M
A market capitalization between $300 million and $2 billion places ASPE in the small capitalization category.
